Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 1 of 1 for:    NCT00749346
Previous Study | Return to List | Next Study

NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00749346
Recruitment Status : Completed
First Posted : September 9, 2008
Last Update Posted : September 27, 2011
Information provided by (Responsible Party):
NovoCure Ltd.

Brief Summary:
An open-label phase I-II trial will be performed in 42 patients with pretreated locally advanced non-small cell lung cancer. The trial is designed to estimate the efficacy and to determine safety of NovoTTF-100L treatment combined with Pemetrexed for advanced NSCLC patients. Patients will receive standard Pemetrexed therapy (at 500 mg/m2 iv q3w for 3 cycles) concomitant to NovoTTF-100L therapy (12 hours a day, daily until the end of all three cycles of Alimta). Repeat treatments with Alimta + NovoTTF-100L will be offered as long as the patient is stable or responding. If there is a in-field response with progression outside of the NovoTTF field, Pemetrexed is to be stopped and third line chemotherapy with Docetaxel is to be initiated (35 mg/m2 weekly, d1, 8, 15, q 28 d).

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer NSCLC Device: NovoTTF-100L Phase 1 Phase 2

Detailed Description:

The trial will be conducted in two stages. Fourteen patients will be recruited to a phase I stage of the trial. After all 14 patients have received 3 courses of Alimta (9 weeks of NovoTTF-100L treatment), these patients will be analyzed for toxicity. If the incidence of device related serious adverse events is < 20%, the trial will continue to the second stage where 42 patients will be assessed for safety and efficacy as part of a phase II study (including the first 14 patients in the phase I study).

Efficacy will be assessed based on local disease control in the lungs and liver, time to systemic disease progression, and overall survival. Patients will be followed for at least 6 months after the last course of NovoTTF-100L is applied to assess survival.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 42 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Pilot Study of NovoTTF-100L in Combination With Pemetrexed (Alimta®) for Advanced Non-small Cell Lung Cancer
Study Start Date : May 2008
Actual Primary Completion Date : July 2011
Actual Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Arm Intervention/treatment
Experimental: A
Treatment with concomitant Alimta and NovoTTF-100L
Device: NovoTTF-100L
TTFields treatment 12h/d for the duration of the study (until progression)concomitant to standard Alimta dosing
Other Names:
  • TTFields
  • Pemetrexed
  • Alimta
  • Electric fields

Primary Outcome Measures :
  1. Device related toxicity [ Time Frame: until 2 months after treatment termination ]

Secondary Outcome Measures :
  1. Time to progression [ Time Frame: Six months after recruitment of the last patient in the trial ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)
  • Stage IV or IIIB with malignant pleural effusion, also locally advanced NSCLC not otherwise amenable to local treatment (surgery or radiotherapy)
  • One line of prior chemotherapy
  • Measurable disease
  • Greater or equal to 18 years
  • Life expectancy of at least 12 weeks
  • ECOG performance status 0-2
  • Laboratory requirements at entry:
  • Blood cell counts:
  • Absolute neutrophils ≥ 1.0 x 109/L
  • Platelets ≥100 x 109/L
  • Hemoglobin ≥ 10 g/dl
  • Renal function:
  • Creatinine clearance ≥ 45 mL/min
  • Hepatic functions:
  • ASAT and ALAT ≤ 3 x UNL
  • Alkaline phosphatase ≤ 5 x UNL
  • Signed informed consent prior to start protocol specific requirements
  • Pregnancy test (β-HCG) must be negative (needed only for women of childbearing potential).

Exclusion Criteria:

  • Known brain metastases or meningeal carcinomatosis
  • Other serious concomitant illness of medical conditions:
  • Congestive heart failure or angina pectoris except if it is medically controlled.
  • Previous history of myocardial infarction within 1 year from study entry.
  • Uncontrolled hypertension or arrhythmias
  • Implanted pacemaker, defibrillator or deep brain stimulation device
  • History of significant neurologic or psychiatric disorders including dementia or seizures
  • Active infection requiring iv antibiotics
  • Active ulcer, unstable diabetes mellitus or other contra-indication to corticosteroid therapy
  • Concurrent treatment with other experimental drugs
  • Participation in clinical trials with other experimental agents within 30 days of study entry
  • Psychological, familial, sociological or geographical conditions which don't permit medical follow-up and compliance with the study protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00749346

Layout table for location information
Basel, Switzerland
Kantonspital Graubunden
Chur, Switzerland
Kantonspital Fribourg
Fribourg, Switzerland
Kantonspital Winterthur
Winterthur, Switzerland
Sponsors and Collaborators
NovoCure Ltd.
Layout table for investigator information
Principal Investigator: Miklos Pless, MD Kantonspital Winterthur
Additional Information:
Layout table for additonal information
Responsible Party: NovoCure Ltd. Identifier: NCT00749346    
Other Study ID Numbers: EF-15
First Posted: September 9, 2008    Key Record Dates
Last Update Posted: September 27, 2011
Last Verified: September 2011
Keywords provided by NovoCure Ltd.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Folic Acid Antagonists
Nucleic Acid Synthesis Inhibitors